GlassScriptPhysician profile
Kalil M Masri
NPI 1750332573
$100,410.28
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86K · 2020: $14K · 2022: $95.43.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $54,142.67 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $31,629.57 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $9,503.62 | 2019-2020 | |
| Abbott Laboratories | $1,562.31 | 2019-2020 | |
| Boston Scientific Corporation | $1,482.83 | 2019-2020 | |
| Pfizer INC. | $863.39 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $364.36 | 2019-2022 | |
| Amgen INC. | $232.52 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $143.37 | 2019 | |
| Edwards Lifesciences Corporation | $115.00 | 2019 | |
| Terumo Medical Corporation | $107.03 | 2019 | |
| United Therapeutics Corporation | $63.07 | 2019 | |
| Abiomed | $57.42 | 2019-2020 | |
| Ekos Corporation | $54.01 | 2019 | |
| Inari Medical, INC. | $32.36 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.21 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.71 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.83 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kalil Masri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.